Lantheus (NASDAQ:LNTH) Releases FY24 Earnings Guidance

Lantheus (NASDAQ:LNTH) updated its FY24 earnings guidance on Wednesday. The company provided EPS guidance of $6.65-6.70 for the period, compared to the consensus EPS estimate of $6.66. The company issued revenue guidance of $1.51-1.52 billion, compared to the consensus revenue estimate of $1.52 billion. Lantheus also updated its FY 2024 guidance to 6.650-6.700 EPS.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on LNTH. Truist Financial reiterated a “buy” rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research note on Friday. JMP Securities lowered their price target on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a report on Thursday. Redburn Atlantic assumed coverage on shares of Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective on the stock. Leerink Partners boosted their target price on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, July 11th. Finally, B. Riley lifted their price target on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.50.

Lantheus Stock Performance

LNTH traded down $0.82 during trading on Friday, hitting $87.50. 1,617,957 shares of the stock were exchanged, compared to its average volume of 993,185. The firm has a market capitalization of $6.08 billion, a P/E ratio of 14.66 and a beta of 0.51. Lantheus has a 1-year low of $50.20 and a 1-year high of $126.89. The stock has a fifty day moving average price of $107.71 and a two-hundred day moving average price of $95.52. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company had revenue of $378.73 million for the quarter, compared to the consensus estimate of $373.58 million. As a group, sell-side analysts predict that Lantheus will post 5.99 earnings per share for the current year.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.10% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.